Related Experiment Videos
Bone loss in patients with inflammatory bowel disease: a prospective study
C Roux1, V Abitbol, S Chaussade
1Clinique de Rhumatologie, Hôpital Cochin, Université René Descartes, Paris, France.
Summary
Patients with inflammatory bowel disease (IBD) experience significant bone loss, particularly those on oral steroids. However, individuals with ileoanal anastomosis show stable bone density, indicating a protective effect.
Area of Science:
- Gastroenterology and Hepatology
- Endocrinology
- Orthopedics
Background:
- Inflammatory bowel disease (IBD) encompasses Crohn's disease and ulcerative colitis.
- IBD is associated with increased risk of bone loss and fractures.
- Oral steroid use is common in IBD management and a known risk factor for osteoporosis.
Purpose of the Study:
- To prospectively evaluate the rate of bone mineral density loss in patients with IBD.
- To compare bone loss rates across different IBD subtypes and surgical interventions.
- To assess the impact of oral steroid therapy on bone density in IBD patients.
Main Methods:
- Prospective study of 35 IBD patients (Crohn's disease, ulcerative colitis).
- Bone mineral density measured at lumbar spine and femoral neck using dual-energy X-ray absorptiometry.
- Follow-up period of 19 months, with analysis of oral steroid use.
Main Results:
- Significant annual bone loss observed in Crohn's disease (-3.1%) and ulcerative colitis without ileoanal anastomosis (-6.4%).
- No bone loss detected in ulcerative colitis patients with ileoanal anastomosis (+2.0%).
- Patients on oral steroids showed greater annual lumbar bone density loss (-6.2%) compared to those without (-0.9%).
Conclusions:
- Patients with IBD are at risk for lumbar and femoral bone loss.
- Ileal pouch-anal anastomosis may prevent bone loss in ulcerative colitis patients.
- Oral steroid use exacerbates bone loss in the IBD population.